100 related articles for article (PubMed ID: 12732176)
1. Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC.
Zhang L; Lukasik SM; Speck NA; Bushweller JH
Blood Cells Mol Dis; 2003; 30(2):147-56. PubMed ID: 12732176
[TBL] [Abstract][Full Text] [Related]
2. Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit.
Zhang L; Li Z; Yan J; Pradhan P; Corpora T; Cheney MD; Bravo J; Warren AJ; Bushweller JH; Speck NA
J Biol Chem; 2003 Aug; 278(35):33097-104. PubMed ID: 12807883
[TBL] [Abstract][Full Text] [Related]
3. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.
Lukasik SM; Zhang L; Corpora T; Tomanicek S; Li Y; Kundu M; Hartman K; Liu PP; Laue TM; Biltonen RL; Speck NA; Bushweller JH
Nat Struct Biol; 2002 Sep; 9(9):674-9. PubMed ID: 12172539
[TBL] [Abstract][Full Text] [Related]
4. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
Nagata T; Werner MH
J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
[TBL] [Abstract][Full Text] [Related]
5. Energetic contribution of residues in the Runx1 Runt domain to DNA binding.
Li Z; Yan J; Matheny CJ; Corpora T; Bravo J; Warren AJ; Bushweller JH; Speck NA
J Biol Chem; 2003 Aug; 278(35):33088-96. PubMed ID: 12807882
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
7. CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium.
Yan J; Liu Y; Lukasik SM; Speck NA; Bushweller JH
Nat Struct Mol Biol; 2004 Sep; 11(9):901-6. PubMed ID: 15322525
[TBL] [Abstract][Full Text] [Related]
8. Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).
Gu TL; Goetz TL; Graves BJ; Speck NA
Mol Cell Biol; 2000 Jan; 20(1):91-103. PubMed ID: 10594012
[TBL] [Abstract][Full Text] [Related]
9. The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding.
Bäckström S; Wolf-Watz M; Grundström C; Härd T; Grundström T; Sauer UH
J Mol Biol; 2002 Sep; 322(2):259-72. PubMed ID: 12217689
[TBL] [Abstract][Full Text] [Related]
10. Drosophila homologs of the proto-oncogene product PEBP2/CBF beta regulate the DNA-binding properties of Runt.
Golling G; Li L; Pepling M; Stebbins M; Gergen JP
Mol Cell Biol; 1996 Mar; 16(3):932-42. PubMed ID: 8622696
[TBL] [Abstract][Full Text] [Related]
11. Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.
Tang YY; Shi J; Zhang L; Davis A; Bravo J; Warren AJ; Speck NA; Bushweller JH
J Biol Chem; 2000 Dec; 275(50):39579-88. PubMed ID: 10984496
[TBL] [Abstract][Full Text] [Related]
12. The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.
Kanto S; Chiba N; Tanaka Y; Fujita S; Endo M; Kamada N; Yoshikawa K; Fukuzaki A; Orikasa S; Watanabe T; Satake M
Leukemia; 2000 Jul; 14(7):1253-9. PubMed ID: 10914550
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.
Nagata T; Gupta V; Sorce D; Kim WY; Sali A; Chait BT; Shigesada K; Ito Y; Werner MH
Nat Struct Biol; 1999 Jul; 6(7):615-9. PubMed ID: 10404214
[TBL] [Abstract][Full Text] [Related]
14. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Tahirov TH; Inoue-Bungo T; Morii H; Fujikawa A; Sasaki M; Kimura K; Shiina M; Sato K; Kumasaka T; Yamamoto M; Ishii S; Ogata K
Cell; 2001 Mar; 104(5):755-67. PubMed ID: 11257229
[TBL] [Abstract][Full Text] [Related]
15. The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation.
Tanaka Y; Fujii M; Hayashi K; Chiba N; Akaishi T; Shineha R; Nishihira T; Satomi S; Ito Y; Watanabe T; Satake M
Oncogene; 1998 Aug; 17(6):699-708. PubMed ID: 9715271
[TBL] [Abstract][Full Text] [Related]
16. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.
Kamikubo Y; Zhao L; Wunderlich M; Corpora T; Hyde RK; Paul TA; Kundu M; Garrett L; Compton S; Huang G; Wolff L; Ito Y; Bushweller J; Mulloy JC; Liu PP
Cancer Cell; 2010 May; 17(5):455-68. PubMed ID: 20478528
[TBL] [Abstract][Full Text] [Related]
17. Crystallization and preliminary studies of the DNA-binding runt domain of AML1.
Bäckström S; Huang SH; Wolf-Watz M; Xie XQ; Härd T; Grundström T; Sauer UH
Acta Crystallogr D Biol Crystallogr; 2001 Feb; 57(Pt 2):269-71. PubMed ID: 11173476
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain.
Crute BE; Lewis AF; Wu Z; Bushweller JH; Speck NA
J Biol Chem; 1996 Oct; 271(42):26251-60. PubMed ID: 8824275
[TBL] [Abstract][Full Text] [Related]
20. Overexpression, purification, and biophysical characterization of the heterodimerization domain of the core-binding factor beta subunit.
Huang X; Crute BE; Sun C; Tang YY; Kelley JJ; Lewis AF; Hartman KL; Laue TM; Speck NA; Bushweller JH
J Biol Chem; 1998 Jan; 273(4):2480-7. PubMed ID: 9442100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
